| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446517 | European Journal of Cancer | 2012 | 14 Pages |
Abstract
According to the definition for rare tumours by RARECARE (incidence < 6 per 100,000), as well as according to the definition for rare diseases by the European Commission (prevalence < 50 per 100,000) the H&N cancers described in this paper should be considered rare and diagnosis and treatment of these cancers should therefore be centralised.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
B.A.C. Van Dijk, G. Gatta, R. Capocaccia, D. Pierannunzio, P. Strojan, L. Licitra, The RARECARE Working Group The RARECARE Working Group,